Completed PHASE3 INTERVENTIONAL 2-arm NCT01583426

Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) (GeparSepto)

A Randomized Phase III Trial Comparing Nanoparticle-based Paclitaxel With Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Patients With Early Breast Cancer (GeparSepto)

Sponsor: Celgene Corporation

Conditions Breast Cancer Female NOS HER-2 Positive Breast Cancer Inflammatory Breast Cancer Inflammatory Breast Cancer Stage IV Invasive Ductal Breast Cancer Mucinous Breast Cancer Stage II Tubular Breast Cancer Stage II Tubular Breast Cancer Stage III

Interventions Paclitaxel nab-Paclitaxel

Updated 8 times since 2017 Last updated: Aug 4, 2020 Started: Jul 31, 2012 Primary completion: Dec 31, 2018 Completion: Dec 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01583426, this PHASE3 trial focuses on Breast Cancer Female NOS and HER-2 Positive Breast Cancer and remains completed. Sponsored by Celgene Corporation, it has been updated 8 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Apr 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Apr 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Sep 2020 — Jan 2021 [monthly]

Completed PHASE3

Status: Unknown Status → Completed

▶ Show 3 earlier versions

Jan 2019 — Sep 2020 [monthly]

Unknown Status PHASE3

Status: Active Not Recruiting → Unknown Status
Jun 2018 — Jan 2019 [monthly]

Active Not Recruiting PHASE3
Jan 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE3

First recorded

Jul 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celgene Corporation
GBG Forschungs GmbH
Roche Pharma AG

Data source: GBG Forschungs GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Berlin, Germany